Question 25

Errors associated with Topamax may be appropriately reported to ISMP MERP.

Errors related to Topamax can be reported to the Institute for Safe Medication Practices (ISMP) Medication Error Reporting Program (MERP) due to the high potential for medication errors involving this product.

A) Varivax

Varivax, a vaccine for varicella, is less likely to be reported to ISMP MERP for errors, as vaccines typically have a different reporting structure focused more on adverse events than on medication errors. Errors with vaccines are often reported to the Vaccine Adverse Event Reporting System (VAERS) rather than ISMP MERP.

B) M-M-R II

Similar to Varivax, M-M-R II, which is a vaccine for measles, mumps, and rubella, is primarily reported for adverse effects rather than medication errors. Reporting for this product would not typically go through ISMP MERP but would follow vaccine-related reporting protocols.

C) Gardasil 9

Gardasil 9 is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). As with the other vaccines, errors associated with Gardasil 9 would be more appropriate for reporting to VAERS rather than ISMP MERP, making it unsuitable for this context.

D) Topamax

Topamax, an anticonvulsant medication, is frequently involved in medication errors due to its complex dosing and potential for confusion with other medications. Therefore, errors related to Topamax are relevant for reporting to ISMP MERP, as the program focuses on improving medication safety and reducing errors.

Conclusion

Topamax is the only product among the options that should be reported to ISMP MERP due to its association with medication errors. In contrast, Varivax, M-M-R II, and Gardasil 9 are vaccines that fall under different reporting guidelines primarily focused on adverse events, not medication errors. This distinction highlights the importance of understanding the nature of the products and the appropriate channels for reporting errors.